ARS Pharmaceuticals, Inc.
SPRYAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 8, 2026 | Leerink Partners | $15.00(+167%) | $5.62 | TheFly | |
| Apr 9, 2026 | Northland Securities | $25.00(+202%) | $8.27 | TheFly | |
| Mar 10, 2026 | Leerink Partners | Roanna Ruiz | $26.00(+180%) | $9.28 | StreetInsider |
| Nov 4, 2025 | Roth Capital | Kyle Bauser | $30.00(+257%) | $8.41 | TheFly |
| Sep 26, 2025 | Raymond James | $32.00(+230%) | $9.69 | TheFly | |
| Aug 19, 2024 | Cantor Fitzgerald | Josh Schimmer | $30.00(+111%) | $14.24 | TheFly |
| Aug 12, 2024 | Raymond James | Strong Buy | $22.00(+103%) | $10.85 | TheFly |
| Jul 25, 2024 | Raymond James | Ryan Deschner | $18.00(+73%) | $10.40 | TheFly |
| Mar 5, 2024 | Leerink Partners | Roanna Ruiz | $18.00(+108%) | $8.65 | StreetInsider |
| Dec 13, 2022 | Leerink Partners | $14.00(+97%) | $7.12 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Cantor Fitzgerald | maintain | Overweight | Nov 6, 2026 |
| Raymond James | downgrade | Strong Buy →Outperform | Nov 6, 2026 |
| Leerink Partners | maintain | Outperform | Aug 13, 2026 |
| Leerink Partners | maintain | Outperform | Jun 25, 2026 |
| Cantor Fitzgerald | maintain | Overweight | May 28, 2026 |
| Raymond James | maintain | Strong Buy | Jan 14, 2025 |
| Leerink Partners | maintain | Outperform | Jan 13, 2025 |
| Cantor Fitzgerald | maintain | Overweight | Oct 8, 2024 |
| Leerink Partners | maintain | Outperform | Sep 20, 2024 |
| Cantor Fitzgerald | maintain | Overweight | Sep 16, 2024 |
| Cantor Fitzgerald | maintain | Overweight | Sep 9, 2024 |
| Raymond James | upgrade | Outperform →Strong Buy | Aug 13, 2024 |
| Wedbush | maintain | Outperform | Mar 11, 2024 |
| Leerink Partners | upgrade | Market Perform →Outperform | Mar 5, 2024 |
| Wedbush | maintain | Outperform | Nov 13, 2023 |
| Wedbush | maintain | Outperform | Sep 21, 2023 |
| William Blair | downgrade | Outperform →Market Perform | Sep 20, 2023 |
| Wedbush | maintain | Outperform | Aug 14, 2023 |
| Wedbush | maintain | Outperform | Jun 21, 2023 |
| Wedbush | maintain | Outperform | May 18, 2023 |
| Wedbush | maintain | Outperform | May 12, 2023 |
| Goldman Sachs | downgrade | Buy →Neutral | Apr 3, 2022 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Mar 31, 2022 |
| SVB Leerink | downgrade | Outperform →Market Perform | Mar 31, 2022 |
| Stifel | downgrade | Buy →Hold | Mar 31, 2022 |
Earnings History
Next report: Mar 8, 2027 · EPS est. $-0.35| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.36 | $-0.30 | $37.7M | $42.0M |
| Aug 13, 2026 | $-0.63 | $-0.48 | $33.7M | $31.3M |
| May 15, 2026 | $-0.61 | $-0.53 | $22.7M | $22.2M |
| Mar 9, 2026 | $-0.42 | $-0.42 | $28.1M | $25.6M |
| Nov 10, 2025 | $-0.52 | $-0.45 | $32.5M | $25.6M |
| Aug 13, 2025 | $-0.46 | $-0.41 | $15.7M | $27.7M |
| May 14, 2025 | $-0.35 | $-0.35 | $8.0M | $14.7M |
| Mar 20, 2025 | $0.52 | $-0.04 | $86.6M | $12.8M |
News
ARS Pharmaceuticals (NASDAQ:SPRY) on Thursday reported weaker-than-expected results for the third quarter.
ARS Pharmaceuticals, Inc. ( SPRY ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Donn Casale - CEO, President & Director Meg Smith Kathleen Scott - Chief Financial Officer Conference Call Participants Monique Allaire - Thrust Strategic Communications Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Frank Wang Zhong - Leerink Partners LLC, Research Division Lachlan Hanbury-Brown - William Blair & Company L.L.C., Research Division Presentation Operator Good af…
ARS Pharmaceuticals NASDAQ: SPRY reported $33.4 million in third-quarter U.S. net product revenue from its needle-free epinephrine treatment neffy and reaffirmed its goal of reaching cash flow breakeven by the end of 2027.
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.52 per share a year ago.
ARS Pharmaceuticals is rated Buy, with current market pricing disconnected from fundamental pipeline value despite commercial setbacks. neffy, the flagship intranasal epinephrine spray, faces slow adoption and insurance hurdles but shows potential for significant market share and revenue. Management pivots to a leaner, targeted prescriber approach, aiming for late-2027 cash-flow breakeven while addressing heavy cash burn and term debt.
ARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions, today announced the company will host a conference call and webcast on Thursday, November 5, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to review its third quarter 2026 financial results.
[url="]Schall, Brown and Schwartz LLP[/url] (âSBSâ), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Ph
LOS ANGELES--(BUSINESS WIRE)---- $SPRY--SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law.
NEW YORK--(BUSINESS WIRE)---- $SPRY #ARS--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ARS Pharmaceuticals Inc. ("“ARS Pharmaceuticals” or the “Company”) (NASDAQ: SPRY) and reminds investors of the October 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, Califor…
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS LawPR NewswireLOS ANGELES, Oct. 5, 2026LOS ANGELES, Oct. 5,
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRYPR NewswireNEW YORK, Oct. 5, 2026NEW YORK,
NEW YORK, Oct. 5, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ: SPRY) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of SPRY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
LOS ANGELES, Oct. 5, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ: SPRY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of SPRY during the class period listed are encouraged to con…
New York, New York--(Newsfile Corp. - October 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased ARS Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a c…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ARS Pharmaceuticals between March 9, 2026 and June 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ARS Pharmaceuticals between March 9, 2026 and June 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--…
New York, New York--(Newsfile Corp. - October 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased ARS Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a c…
NEW YORK, Oct. 2, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff deadline. So what: If you purchased ARS Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem…
NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the “Class Period”), of the important October 5, 2026 lead plaintiff deadline.